Renalytix Plc
RENX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 31.1% | -32.7% | 14.6% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 40% | 6.8% | 20.6% | 30.9% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -573.3% | -1,293.5% | -1,244.6% | -1,790.7% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | £0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | £0 | £0 | £0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -680% | -1,461.6% | -1,340.2% | -1,524.4% |
| EPS | -0.21 | -0.31 | -0.55 | -0.62 |
| % Growth | 32.3% | 43.6% | 11.3% | – |
| EPS Diluted | -0.21 | -0.31 | -0.55 | -0.67 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -710% | -1,246% | -1,225.8% | -1,774.2% |